** Shares in Gubra GUBRA.CO surge 29% at market open after the Danish biotech company signed a licensing deal with AbbVie ABBV.N to develop an amylin analog for obesity treatment
** The partnership marks AbbVie's entrance into the obesity field, the companies say in a press release
** Terms of the deal include $305 million as an upfront payment to Gubra and $1.875 billion in potential milestones, they add
** Analysts at Van Lanschot Kempen view the terms as "attractive", saying they appear to be higher than the broker's valuation
** Kempen adds AbbVie is a good partner for Gubra, as it can accelerate mid- and late-stage development of the GUBamy amylin analog programme, while offering infrastructure for a commercial launch
** Gubra's shares were up 19% by 0824 GMT, on track for their best day ever
(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。